glp 1 agonists with cardiovascular benefit agonist risks GLP-1 receptor agonist-based therapies and risk: a review of Cardiovascular Protective Properties of GLP-1

39,40 Further research is needed to clarify this potential risk

Ozempic / Mounjaro when prescribed for type 2 diabetes

Role of Prohormone Convertases in the Tissue-Specific Processing of Proglucagon

GLP-1 effects on -cell proliferation and apoptosis The prevalence of type 2 diabetes correlates with excess body weight and also increases with age [525]

2 This effect may arise from mechanisms involving reduced ectopic fat accumulation and better cellular glucose uptake

This requires carefully designed clinical trials that account for commercial dynamics, as well as pre-launch disease education to prime market understanding regarding where new therapies fit in the treatment paradigm